Objective: To investigate the cell cycle, cell apoptosis and DNA damage induced by acrylamide (AA) in L-02 human liver embryo cell line.
Methods: The rate of cell survivors, cell cycle, cell apoptosis and DNA damage were measured respectively after L-02 cell were exposed to 0.01, 0.1, 0.5, 1.0, 2.5, 5.0 and 7.5 mmol/L AA for 12h and 24h in vitro.
Results: The rates of cellular survivors in the low (0.01 mmol/L and 0.1 mmol/) dose AA-treated group were higher than those in control group, but those in the middle (0.5, 1.0 and 2.5 mmol/L) and high (5.0 mmol/L and 7.5 mmol/L) dose AA-treated groups were significantly lower than those in control group (P < 0.05). The rate of cell in G1 stage was reduced along with the promotion of AA, and the middle and high (> 1.0 mmol/L) dose AA-treated groups were significantly lower than the control group (P < 0.05), while the rate of cell in S stage was in reverse. The percentages of apoptosis were significantly higher than that of the control group in the high dose AA-treated groups (P < 0.05). The percents of tail DNA and Oliver Tail Moment (OTM) were significantly higher than that of the control group in the middle and high (> 1.0 mmol/L) dose AA-treated groups (P < 0.05).
Conclusion: AA could induce the confusion and apoptosis of L-02 cell, and has impairment effect on DNA.
Download full-text PDF |
Source |
---|
Int J Hematol
February 2025
Department of Hematology, Kobe City Medical Center General Hospital, 2-1-1, Minatojima-Minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan.
Eltrombopag (EPAG), an oral thrombopoietin receptor agonist, has shown excellent efficacy in patients with aplastic anemia (AA) alone or in combination with immunosuppressive therapy. EPAG also has the unexpected ability to chelate polyvalent cations, including iron. However, the association between long-term EPAG use and iron deficiency anemia (IDA) remains unclear.
View Article and Find Full Text PDFDermatol Ther (Heidelb)
July 2024
Brigham and Women's Hospital, Boston, MA, USA.
Introduction: Alopecia areata (AA) is an autoimmune disease associated with high rates of emotional and psychosocial distress. The analysis reported here describes the evolution of measures assessing health-related quality of life (HRQoL) and symptoms of anxiety and depression up to week 104 in patients who achieved sustained scalp hair regrowth during treatment with baricitinib in the BRAVE-AA phase III trials.
Methods: This post-hoc analysis included data from the double-blind, parallel-group, randomized, placebo-controlled phase III trials BRAVE-AA1 (ClinicalTrials.
J Inflamm Res
November 2023
Department of Pediatrics, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, 621000, People's Republic of China.
Objective: To summarize the clinical features and treatment experiences of patients with Kawasaki disease (KD)-associated acute abdomen (KD-AA).
Methods: We conducted a retrospective case-control study of patients with KD-AA treated at our hospital between January 2006 and November 2022.
Results: Of the 917 children with KD, 43 (4.
Stress Health
June 2024
Department of Internal Medicine, Yerevan State Medical University Named after Mkhitar Heratsi, Yerevan, Armenia.
The aim of this study was to determine whether ascorbic acid (AA) supplementation can lower plasma levels of Cortisol and dehydroepiandrosterone-sulphate (DHEA-S) in patients diagnosed with functional hypercortisolemia due to unspecified chronic stress. Study includes data from 69 female with elevations in the cortisol and DHEA-S levels. Duration of follow-up was 2 months.
View Article and Find Full Text PDFEur J Haematol
March 2024
Division of Hematology and Medical Oncology, Department of Internal Medicine, University of Michigan Medical School, Michigan Medicine, Ann Arbor, Michigan, USA.
Aplastic anemia (AA) is a rare bone marrow failure disorder that is treated with either allogeneic stem cell transplant or immunosuppressive therapy (IST) consisting of antithymocyte globulin (ATG), cyclosporine (CSA), and eltrombopag. While outcomes are favorable in younger patients, older patients (>60) have significantly worse long-term survival. The dose of ATG is often reduced in older patients and those with multiple comorbidities given concerns for tolerability.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!